Pharma Generics

Pharma Generics
  • Pininvest Analysis

The rise and fall of Israeli industry leader Teva TEVA/NYSE, reaching 59$ at the end of March 2016 only to fall off a cliff in August 2017,  is a story of extreme challenges buffeting the generics pharma industry

With aging populations in most developed countries, exploding healthcare costs and creaking insurance systems, and with better health coverage coming to the emerging markets, generics are strongly supported by national and local health authorities

But national as well as private health insurers press for more control over healthcare expenses. Increased competition, with more FDA approved generics brought on the US market every year, and sharper negotiations point towards commoditization and margin pressure

Take a closer look

Pharma Generics • Updated:

Name Ticker Exchange Sector Industry Currency Cur.Price Mkt.Cap Perf. Vol. Risk Contrib. MDD
 
Abbott Laboratories ABT NYSE Health Care Drug Manufacturers - Diversified USD 76.75 135 B 32.9% 22%   10% -12%
Akorn AKRX NASDAQ Health Care Drug Manufacturers - Diversified USD 2.91 365 M -78.5% 112%   4% -86%
Bausch Health Companies BHC NYSE Health Care Drug Manufacturers - Diversified USD 23.01 8.1 B 31.2% 46%   26% -38%
Fresenius FSNUY OTC Health Care Healthcare Facilities & Services USD 14.18 - -25.7% 38%   8% -46%
Hikma Pharmaceuticals HKMPY OTC Health Care Drug Manufacturers - Generic USD 44.81 - 28.4% 37%   7% -20%
Hypermarcas SA HYPMY OTC Health Care Drug Manufacturers - Generic USD 6.35 - -32.5% 41%   4% -33%
Mylan MYL NASDAQ Health Care Drug Manufacturers - Generic USD 26.44 14 B -32.1% 37%   9% -38%
Novartis NVS NYSE Health Care Drug Manufacturers - Diversified USD 77.82 180 B 19.4% 21%   6% -22%
Perrigo Co PRGO NYSE Health Care Drug Manufacturers - Generic USD 49.20 6.7 B -35.8% 50%   11% -55%
Teva Pharmaceutical Industries TEVA NYSE Health Care Drug Manufacturers - Diversified USD 15.00 16 B -13.1% 41%   14% -45%